Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells

Carcinogenesis

Volumn 30, Issue 3, 2009, Pages 449-456

  Abedin, S Asad ^a   Thorne, James L ^a   Battaglia, Sebastiano ^a   Maguire, Orla ^b   Hornung, Laura B ^b   Doherty, Alan P ^c   Mills, Ian G ^d   Campbell, Moray J ^b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FARNESOID X RECEPTOR; NUCLEAR RECEPTOR COREPRESSOR; NUCLEAR RECEPTOR COREPRESSOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RNA; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; VORINOSTAT;

ANIMAL CELL; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DIETARY INTAKE; EPIGENETICS; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MICROFLUIDIC ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL LINE, TUMOR; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LIGANDS; NUCLEAR PROTEINS; PPAR GAMMA; RECEPTORS, CALCITRIOL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REPRESSOR PROTEINS; RNA INTERFERENCE; TRANSCRIPTION FACTORS; URINARY BLADDER NEOPLASMS;

EID: 62349138999     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp005     Document Type: Article

References (49)

1. Crescioli,C. et al. (2005) Human bladder as a novel target for vitamin D receptor ligands. J. Clin. Endocrinol. Metab., 90, 962-972.
2. Shen,S.S. et al. (2006) Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer, 106, 2610-2616.
3. Kassouf,W. et al. (2006) Inhibition of bladder tumor growth by 1,1-bis(3′-indolyl)-1-(p-substitutedphenyl)methanes: A new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res., 66, 412-418.
4. Makishima,M. et al. (2002) Vitamin D receptor as an intestinal bile acid sensor. Science, 296, 1313-1316.
5. Shaw,N. et al. (2003) Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor beta/delta. J. Biol. Chem., 278, 41589-41592.
6. Rosenfeld,M.G. et al. (2006) Sensors and signals: A coactivator/ corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev., 20, 1405-1428.
7. Chen,J.D. et al. (1995) A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature, 377, 454-457.
8. Fernandes,I. et al. (2003) Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Mol. Cell, 11, 139-150.
9. Li,J. et al. (2000) Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J., 19, 4342-4350.
10. Hatchell,E.C. et al. (2006) SLIRP, a small SRA binding protein, is a nuclear receptor corepressor. Mol. Cell, 22, 657-668.
11. Fischle,W. et al. (2002) Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell, 9, 45-57.
12. Kouzarides,T. (2007) Chromatin modifications and their function. Cell 128, 693-705.
13. Khanim,F.L. et al. (2004) Altered SMRT levels disrupt vitamin D(3) receptor signalling in prostate cancer cells. Oncogene, 23, 6712-6725.
14. Banwell,C.M. et al. (2006) Altered nuclear receptor corepressor expression attenuates vitamin d receptor signaling in breast cancer cells. Clin. Cancer Res., 12, 2004-2013.
15. Wang,J. et al. (1998) ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/ mSin3/HDAC1 complex. Proc. Natl Acad. Sci. USA, 95, 10860-10865.
16. Rashid,S.F. et al. (2001) Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene, 20, 1860-1872.
17. Vaisanen,S. et al. (2005) Spatio-temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1alpha,25-dihydroxyvitamin D(3). J. Mol. Biol., 350, 65-77.
18. Chatterjee,B. et al. (2005) Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. Methods Enzymol., 400, 165-191.
19. Hodgkinson,C.P. et al. (2003) Microarray analysis of peroxisome proliferator-activated receptor-gamma induced changes in gene expression in macrophages. Biochem. Biophys. Res. Commun., 308, 505-510.
20. Wagner,B.L. et al. (2003) Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol. Cell. Biol., 23, 5780-5789.
21. Saramaki,A. et al. (2006) Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res., 34, 543-554.
22. Fukuchi,J. et al. (2004) Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res. 64, 7686-7689.
23. Huang,Y.C. et al. (2004) Vitamin D(3) receptor/Sp1 complex is required for the induction of p27(Kip1) expression by vitamin D(3). Oncogene, 23, 4856-4861.
24. Liu,J.J. et al. (2005) Expression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-{gamma} ligands induces apoptosis on human myeloid leukemia cells in vitro. Ann. Oncol., 16, 455-459.
25. Dunlop,T.W. et al. (2004) The genes of the coactivator TIF2 and the corepressor SMRT are primary 1alpha,25(OH)(2)D(3) targets. J. Steroid Biochem. Mol. Biol., 89-90, 257-260.
26. Liang,H. et al. (2000) Chromosomal mapping and genomic organization of an evolutionarily conserved zinc finger gene ZNF277. Genomics, 66, 226-228.
27. Krueger,B.J. et al. (2008) LARP7 is a stable component of the 7SK snRNP while P-TEFb, HEXIM1 and hnRNP A1 are reversibly associated. Nucleic Acids Res., 36, 2219-2229.
28. Jeronimo,C. et al. (2007) Systematic analysis of the protein interaction network for the human transcription machinery reveals the identity of the 7SK capping enzyme. Mol. Cell, 27, 262-274.
29. Evans,R.M. (2005) The nuclear receptor superfamily: A rosetta stone for physiology. Mol. Endocrinol., 19, 1429-1438.
30. Carlberg,C. et al. (2006) An integrated biological approach to nuclear receptor signaling in physiological control and disease. Crit. Rev. Eukaryot. Gene Expr., 16, 1-22.
31. Everson,G.T. (1987) Steady-state kinetics of serum bile acids in healthy human subjects: Single and dual isotope techniques using stable isotopes and mass spectrometry. J. Lipid Res., 28, 238-252.
32. Birt,D.F. et al. (1983) Influence of dietary fat on spontaneous lesions of Syrian golden hamsters. J. Natl Cancer Inst., 71, 401-406.
33. Riboli,E. et al. (1991) Diet and bladder cancer in Spain: A multi-centre case-control study. Int. J. Cancer, 49, 214-219.
34. Steinmaus,C.M. et al. (2000) Diet and bladder cancer: A meta-analysis of six dietary variables. Am. J. Epidemiol., 151 693-702.
35. Goodwin,B. et al. (2003) Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc. Natl Acad. Sci. USA, 100, 223-228.
36. Maruyama,T. et al. (2002) Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun., 298, 714-719.
37. Fang,Y. et al. (2004) Bile acids induce mitochondrial ROS, which promote activation of receptor tyrosine kinases and signaling pathways in rat hepatocytes. Hepatology, 40, 961-971.
38. Zandbergen,F. et al. (2005) The G0/G1 switch gene 2 is a novel PPAR target gene. Biochem. J., 392, 313-324.
39. Ge,K. et al. (2002) Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis. Nature, 417, 563-567.
40. Pineda Torra,I. et al. (2004) Identification of DRIP205 as a coactivator for the Farnesoid X receptor. J. Biol. Chem., 279 36184-36191.
41. Desmond,J.C. et al. (2003) The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res., 63, 505-512.
42. Daujat,S. et al. (2002) Crosstalk between CARM1 methylation and CBP acetylation on histone H3. Curr. Biol., 12, 2090-2097.
43. Thomas,C. et al. (2008) Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov., 7, 678-693.
44. Tirona,R.G. et al. (2003) The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat. Med., 9, 220-224.
45. Lucas,B. et al. (2005) HNF4alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma. Oncogene 24, 6418-6431.
46. Black,M.H. et al. (2008) Evidence of interaction between PPARG2 and HNF4A contributing to variation in insulin sensitivity in Mexican Americans. Diabetes, 57, 1048-1056.
47. Campbell,M.J. et al. (2008) A role for the PPARgamma in cancer therapy. PPAR Res., 2008, 314974.
48. Warburg,O. (1956) On the origin of cancer cells. Science, 123 309-14.
49. Campbell,M.J. et al. (2006) The vitamin D receptor as a therapeutic target. Expert Opin. Ther. Targets, 10, 735-748.